Phillips-Medisize Completes Wisconsin Facility Expansion

Phillips-Medisize Corp. has completed a 5,000-square-foot expansion to its Hudson, Wis., design and development center (DDC).
According to the company, the new space will be occupied with expanded biopharmaceutical drug delivery and medical device test engineering capabilities including test method development, test method validation, product characterization, design verification testing, and root cause analysis, among others.

Since 2013 nearly 100 device development professionals were added in the Hudson design and development center. Earlier this year, the company also expanded its pilot manufacturing development class 7 and class 8 clean-room space for drug delivery and med/surgical devices.

The Hudson DDC expansion is the direct result of new business in the biologic/pharma drug delivery, combination products and medtech spaces. New projects include products with complex mechatronic assembly and micro-manufacturing requirements, company leadership noted.

Future expansions or acquisitions also are planned for the existing Europe and China locations, driven by global customers looking for local development and manufacturing services.

Headquartered in Hudson, Wis., Phillips-Medisize is an outsource provider of design and manufacturing services to the drug delivery, consumable diagnostics and medical device, and specialty commercial markets. The company has annual sales of more than $600 million with 80 percent of the total revenue coming from drug delivery, medical device, primary pharmaceutical packaging and diagnostic products such as disposable insulin pens, glucose meters, specialty inhalation drug delivery devices, single-use surgical devices and consumable diagnostic components.

Phillips-Medisize employs more than 3,400 people in 14 locations throughout the United States, Europe, Mexico and China. The company also has design centers in Wisconsin, California, the Netherlands and China.